Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Anti-vimentin, anti-TUFM, anti-NAP1L1 and anti-DPYSL2 nanobodies display cytotoxic effect and reduce glioblastoma cell migration
ID
Zottel, Alja
(
Avtor
),
ID
Jovchevska, Ivana
(
Avtor
),
ID
Šamec, Neja
(
Avtor
),
ID
Mlakar, Jernej
(
Avtor
),
ID
Šribar, Jernej
(
Avtor
),
ID
Križaj, Igor
(
Avtor
),
ID
Skoblar Vidmar, Marija
(
Avtor
),
ID
Komel, Radovan
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(4,45 MB)
MD5: D2723DD457EC226D179EF8156CD6F222
URL - Izvorni URL, za dostop obiščite
https://journals.sagepub.com/doi/10.1177/1758835920915302
Galerija slik
Izvleček
Background: Glioblastoma is a particularly common and very aggressive primary brain tumour. One of the main causes of therapy failure is the presence of glioblastoma stem cells that are resistant to chemotherapy and radiotherapy, and that have the potential to form new tumours. This study focuses on validation of eight novel antigens, TRIM28, nucleolin, vimentin, nucleosome assembly protein 1-like 1 (NAP1L1), mitochondrial translation elongation factor (EF-TU) (TUFM), dihydropyrimidinase-related protein 2 (DPYSL2), collapsin response mediator protein 1 (CRMP1) and Aly/REF export factor (ALYREF), as putative glioblastoma targets, using nanobodies. Methods: Expression of these eight antigens was analysed at the cellular level by qPCR, ELISA and immunocytochemistry, and in tissues by immunohistochemistry. The cytotoxic effects of the nanobodies were determined using AlamarBlue and water-soluble tetrazolium tests. Annexin V/propidium iodide tests were used to determine apoptotsis/necrosis of the cells in the presence of the nanobodies. Cell migration assays were performed to determine the effects of the nanobodies on cell migration. Results: NAP1L1 and CRMP1 were significantly overexpressed in glioblastoma stem cells in comparison with astrocytes and glioblastoma cell lines at the mRNA and protein levels. Vimentin, DPYSL2 and ALYREF were overexpressed in glioblastoma cell lines only at the protein level. The functional part of the study examined the cytotoxic effects of the nanobodies on glioblastoma cell lines. Four of the nanobodies were selected in terms of their specificity towards glioblastoma cells and protein overexpression: anti-vimentin (Nb79), anti-NAP1L1 (Nb179), anti-TUFM (Nb225) and anti-DPYSL2 (Nb314). In further experiments to optimise the nanobody treatment schemes, to increase their effects, and to determine their impact on migration of glioblastoma cells, the anti-TUFM nanobody showed large cytotoxic effects on glioblastoma stem cells, while the anti-vimentin, anti-NAP1L1 and anti-DPYSL2 nanobodies were indicated as agents to target mature glioblastoma cells. The anti-vimentin nanobody also had significant effects on migration of mature glioblastoma cells. Conclusion: Nb79 (anti-vimentin), Nb179 (anti-NAP1L1), Nb225 (anti-TUFM) and Nb314 (anti-DPYSL2) nanobodies are indicated for further examination for cell targeting. The anti-TUFM nanobody, Nb225, is particularly potent for inhibition of cell growth after long-term exposure of glioblastoma stem cells, with minor effects seen for astrocytes. The anti-vimentin nanobody represents an agent for inhibition of cell migration.
Jezik:
Angleški jezik
Ključne besede:
glioblastoma
,
glioblastoma stem cells
,
nanobodies
,
cell migration
,
cytotoxicity
,
vimentin
,
DPYSL2
,
NAP1L1
,
TUFM
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
MF - Medicinska fakulteta
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2020
Št. strani:
29 str.
Številčenje:
Vol. 12
PID:
20.500.12556/RUL-128767
UDK:
616-006
ISSN pri članku:
1758-8359
DOI:
10.1177/1758835920915302
COBISS.SI-ID:
13271299
Datum objave v RUL:
28.07.2021
Število ogledov:
4795
Število prenosov:
460
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Therapeutic advances in medical oncology
Skrajšan naslov:
Ther. adv. med. oncol.
Založnik:
SAGE Publications
ISSN:
1758-8359
COBISS.SI-ID:
519822105
Licence
Licenca:
CC BY-NC 4.0, Creative Commons Priznanje avtorstva-Nekomercialno 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by-nc/4.0/deed.sl
Opis:
Licenca Creative Commons, ki prepoveduje komercialno uporabo, vendar uporabniki ne rabijo upravljati materialnih avtorskih pravic na izpeljanih delih z enako licenco.
Začetek licenciranja:
28.04.2020
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
glioblastom
,
matične celice
,
nanocelice
,
migracija celic
,
citotoksičnost
Projekti
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0104
Naslov:
Funkcijska genomika in biotehnologija za zdravje
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0207
Naslov:
Toksini in biomembrane
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Številka projekta:
P1-0390
Naslov:
Funkcijska genomika in biotehnologija za zdravje
Financer:
ARRS - Agencija za raziskovalno dejavnost Republike Slovenije
Program financ.:
Junior Researcher Grant
Financer:
EC - European Commission
Program financ.:
Interreg
Akronim:
TRANS-GLIOMA
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj